Here are six takeaways:
1. This conversion took place between the two-and three-month evaluations.
2. This patient represents the fifth out of eight patients to experience an AIS grade improvement, representing a 62.5 percent conversion rate.
3. The Objective Performance Criterion for the INSPIRE study indicates five or more of the 20 evaluable patients improve by at least one AIS grade at the six months post-implantation follow-up.
4. If the current five converted patients don’t revert to AIS A before the six-month follow-up, then InVivo will have met the OPC.
5. The INSPIRE study tests the Neuro-Spinal Scaffold’s efficacy and safety for complete thoracic AIS A spinal cord injury.
6. Twenty-three clinical sites around the country are participating in the INSPIRE study.
“Having five patients improve AIS grades so early in the INSPIRE study is a fantastic achievement and a major milestone for InVivo,” said Mark Perrin, CEO and chairman, InVivo. “If we continue to observe AIS conversions at a similar rate, we will dramatically exceed the Objective Performance Criterion measure of study success.”
More articles on devices:
Medtronic, SeaSpine, Zimmer Biomet & more: 17 key notes
Analysts update price targets of NuVasive stock — 3 quick points
DePuy Synthes, Acumed, Stryker market leaders in Japan device market: 5 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
